Stephen EllimanChief Scientific Officer at Orbsen Therapeutics, USA
Dr Stephen Elliman is Orbsen’s Founding Scientist and Chief Scientific Officer. Steve’s PhD focused on describing and defining human stromal cell (SC) populations at UCL in London. He moved to develop SC as a discovery platform at Novartis here in Boston and then obtained a Marie Curie Fellowship to transfer SC technologies to the National University of Ireland in Galway. Steve co-founded Orbsen to identify novel SC surface markers to enable SC purification isolation for therapeutic use. Orbsen has 4 early phase clinical trials assessing the safety & efficacy of ORBCEL in patients with ARDS, autoimmune diseases and kidney disease.